A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab
Tumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents. There are several side effects reported in pa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Case Reports in Rheumatology |
| Online Access: | http://dx.doi.org/10.1155/2013/985914 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556042912792576 |
|---|---|
| author | Hakan Ozkan Ahmet Seckin Cetinkaya Tekin Yildiz Tahsin Bozat |
| author_facet | Hakan Ozkan Ahmet Seckin Cetinkaya Tekin Yildiz Tahsin Bozat |
| author_sort | Hakan Ozkan |
| collection | DOAJ |
| description | Tumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents. There are several side effects reported in patients with adalimumab therapy. Cardiac side effects of adalimumab are rare. Only a few cardiac side effects were reported. A 61-year-old man treated with adalimumab for the last 6 months due to psoriatic arthritis presented with typically acute pleuropericarditis. Chest X-ray and echocardiography demonstrated marked pericardial effusion. Patient was successfully evaluated for the etiology of acute pleuro-pericarditis. Every etiology was excluded except the usage of adalimumab. Adalimumab was discontinued, and patient was treated with 1200 mg of ibuprofen daily. Control chest X-ray and echocardiography after three weeks demonstrated complete resolution of both pleural and pericardial effusions. This case clearly demonstrated the acute onset of pericarditis with adalimumab usage. Acute pericarditis and pericardial effusion should be kept in mind in patients with adalimumab treatment. |
| format | Article |
| id | doaj-art-14f5c22925844ab6a75d05c33b2add4f |
| institution | Kabale University |
| issn | 2090-6889 2090-6897 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Rheumatology |
| spelling | doaj-art-14f5c22925844ab6a75d05c33b2add4f2025-02-03T05:46:25ZengWileyCase Reports in Rheumatology2090-68892090-68972013-01-01201310.1155/2013/985914985914A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with AdalimumabHakan Ozkan0Ahmet Seckin Cetinkaya1Tekin Yildiz2Tahsin Bozat3Department of Cardiology, Medical Park Hospital, Hasim Iscan Cad, Fomara Meydani, No. 1, Osmangazi, 16220 Bursa, TurkeyDepartment of Cardiology, Medical Park Hospital, Hasim Iscan Cad, Fomara Meydani, No. 1, Osmangazi, 16220 Bursa, TurkeyDepartment of Respiratory Disease, Medical Park Hospital, 16220 Bursa, TurkeyDepartment of Cardiology, Medical Park Hospital, Hasim Iscan Cad, Fomara Meydani, No. 1, Osmangazi, 16220 Bursa, TurkeyTumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents. There are several side effects reported in patients with adalimumab therapy. Cardiac side effects of adalimumab are rare. Only a few cardiac side effects were reported. A 61-year-old man treated with adalimumab for the last 6 months due to psoriatic arthritis presented with typically acute pleuropericarditis. Chest X-ray and echocardiography demonstrated marked pericardial effusion. Patient was successfully evaluated for the etiology of acute pleuro-pericarditis. Every etiology was excluded except the usage of adalimumab. Adalimumab was discontinued, and patient was treated with 1200 mg of ibuprofen daily. Control chest X-ray and echocardiography after three weeks demonstrated complete resolution of both pleural and pericardial effusions. This case clearly demonstrated the acute onset of pericarditis with adalimumab usage. Acute pericarditis and pericardial effusion should be kept in mind in patients with adalimumab treatment.http://dx.doi.org/10.1155/2013/985914 |
| spellingShingle | Hakan Ozkan Ahmet Seckin Cetinkaya Tekin Yildiz Tahsin Bozat A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab Case Reports in Rheumatology |
| title | A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab |
| title_full | A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab |
| title_fullStr | A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab |
| title_full_unstemmed | A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab |
| title_short | A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab |
| title_sort | rare side effect due to tnf alpha blocking agent acute pleuropericarditis with adalimumab |
| url | http://dx.doi.org/10.1155/2013/985914 |
| work_keys_str_mv | AT hakanozkan araresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT ahmetseckincetinkaya araresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT tekinyildiz araresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT tahsinbozat araresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT hakanozkan raresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT ahmetseckincetinkaya raresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT tekinyildiz raresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab AT tahsinbozat raresideeffectduetotnfalphablockingagentacutepleuropericarditiswithadalimumab |